United Kingdom
Apoquel Logo

REFERENCES

 

1Apoquel SPC

2Zoetis study:A161-AU-12-096

3Zoetis Study: 1962C-60-09-930 , Cosgrove SB et al, Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis Vet Dermatol 2013; 24: 479–e114 (control of itch within 24hours)

4Zoetis study: Zoetis Study 1962C-60-10-A16 , Cosgrove SB et al, A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587-e142.

5Zoetis Studies: 5962C-85-08-364

6Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297

7Marsella R et al, Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. JAVMA, Vol 241, No. 2, July 15, 2012

8Fleck T et al, Comparison of the onset and anti-pruritic activity of the JAK inhibitor oclacitinib to prednisolone and dexamethasone in an IL-31 canine model of pruritus. Zoetis Study, Study A160R-US-12-057. Abstract NAVDF 2013 Louisville

9Fleck et al., WCVD 2012. Comparison of the janus kinase (JAK) inhibitor oclacitinib and prednisolone in canine models of pruritus. Vet Dermatol 2012; Jul;23(Suppl. 1): FC-36, p38

10Cosgrove SB et al, BSAVA 2014 [Abstract].Efficacy and safety of APOQUEL® (oclacitinib) administered to client-owned dogs enrolled in a long term compassionate care program.

11Zoetis study:1962C-60-10-A02.